Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 18, 2012 18:00 ET | Source: MediciNova, Inc.

MediciNova Extends MN-166 Patent Position in Europe

SAN DIEGO, Nov. 18, 2012 (GLOBE NEWSWIRE) -- MediciNova Inc, a biopharmaceutical company traded on the NASDAQ Global Market (Nasdaq:MNOV) and the Jasdaq Market of the Osaka Securities Exchange (Code...
November 14, 2012 18:00 ET | Source: MediciNova, Inc.

MediciNova to Present at the Fourth World Congress of Emergency Medicine

SAN DIEGO, Nov. 14, 2012 (GLOBE NEWSWIRE) -- MediciNova, Inc. a biopharmaceutical company traded on the NASDAQ Global Market (Nasdaq:MNOV) and the Jasdaq Market of the Osaka Securities Exchange (Code...
November 12, 2012 18:00 ET | Source: MediciNova, Inc.

MediciNova Announces Publication of MN-221 Clinical Results in Journal of Asthma

SAN DIEGO, Nov. 12, 2012 (GLOBE NEWSWIRE) -- MediciNova, Inc. a biopharmaceutical company traded on the NASDAQ Global Market (Nasdaq:MNOV) and the Jasdaq Market of the Osaka Securities Exchange (Code...
November 08, 2012 18:00 ET | Source: MediciNova, Inc.

MediciNova Reports Third Quarter 2012 Results and Update on MN-221 Development

SAN DIEGO, Nov. 8, 2012 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company that is publicly traded on the Nasdaq Global Market (Nasdaq:MNOV) and the Jasdaq Market of the Osaka...
November 07, 2012 18:00 ET | Source: MediciNova, Inc.

MediciNova to Present at the Lazard Capital Markets Healthcare Conference

SAN DIEGO, Nov. 7, 2012 (GLOBE NEWSWIRE) -- MediciNova Inc, a biopharmaceutical company traded on the NASDAQ Global Market (Nasdaq:MNOV) and the Jasdaq Market of the Osaka Securities Exchange (Code...
October 25, 2012 19:00 ET | Source: MediciNova, Inc.

MediciNova Receives a Notice of European Patent Allowance for Treating Progressive Multiple Sclerosis

SAN DIEGO, Oct. 25, 2012 (GLOBE NEWSWIRE) -- MediciNova Inc, a biopharmaceutical company traded on the NASDAQ Global Market (Nasdaq:MNOV) and the Jasdaq Market of the Osaka Securities Exchange (Code...
October 22, 2012 19:00 ET | Source: MediciNova, Inc.

MediciNova Meets With FDA for End-of-Phase 2 Meeting for MN-221 for the Treatment of Acute Exacerbations of Asthma

SAN DIEGO, Oct. 22, 2012 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (Nasdaq:MNOV) and the Jasdaq Market of the Osaka Securities Exchange (Code...
September 04, 2012 19:00 ET | Source: MediciNova, Inc.

NIH Funds UCLA Phase 2 Study of MediciNova's MN-166 in Treating Drug Addiction

LOS ANGELES and SAN DIEGO, Sept. 4, 2012 (GLOBE NEWSWIRE) -- The University of California, Los Angeles' (UCLA's) Department of Family Medicine/Center for Behavioral and Addiction Medicine, and...
August 28, 2012 19:00 ET | Source: MediciNova, Inc.

MediciNova to Present at the Rodman & Renshaw Annual Global Investment Conference on September 11, 2012

SAN DIEGO, Aug. 28, 2012 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company that is publicly traded on the Nasdaq Global Market (Nasdaq:MNOV) and the Jasdaq Market of the Osaka...
August 23, 2012 19:00 ET | Source: MediciNova, Inc.

MediciNova Announces Positive Preliminary Results From a Multi-Day, Repeat-Dose Clinical Trial With MN-221 in Chronic Obstructive Pulmonary Disease Patients

SAN DIEGO, Aug. 23, 2012 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company that is publicly traded on the Nasdaq Global Market (Nasdaq:MNOV) and the Jasdaq Market of the Osaka...